 |
 |

Infant Growth After In Utero Exposure to Zidovudine
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: While Ms Culname and colleagues1 report that children born to human immunodeficiency virus (HIV)infected women and exposed to zidovudine in utero have no difference in growth accretion compared with unexposed counterparts, it is not known whether these children grow less than infants born to healthy seronegative mothers.2
Thirty-two full-term uninfected infants (17 male, 15 female) consecutively born to HIV-infected women in our maternity ward from 1995 through 1997 were categorized as treated (20 infants whose mothers received oral zidovudine from the 14th week of gestation and intravenous zidovudine during delivery) or untreated (12 infants whose mothers did not receive any treatment). Mothers decided whether to receive prophylactic treatment after being informed about the study results of the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.3 No infant was treated with zidovudine at birth. Diagnosis and staging of HIV infection were in accordance with the 1994 Centers . . . [Full Text of this Article]
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
Lack of Long-term Effects of In Utero Exposure to Zidovudine Among Uninfected Children Born to HIV-Infected Women
Mary Culnane, MaryGlenn Fowler, Sophia S. Lee, George McSherry, Michael Brady, Karen O'Donnell, Lynne Mofenson, Steven L. Gortmaker, David E. Shapiro, Gwendolyn Scott, Eleanor Jimenez, Ellen C. Moore, Clemente Diaz, Patricia M. Flynn, Bethann Cunningham, James Oleske, and for the Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams
JAMA. 1999;281(2):151-157.
ABSTRACT
| FULL TEXT
|